Trial Profile
A Phase I/II, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Hmpl 453 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Hutchison MediPharma; HUTCHMED
- 12 Feb 2020 Planned End Date changed from 1 Mar 2020 to 30 Jun 2020.
- 12 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 18 Nov 2019 Planned End Date changed from 1 Oct 2019 to 1 Mar 2020.